Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: What have we learned?

Michael Grundman, Ronald Carl Petersen, David A. Bennett, Howard H. Feldman, Stephen Salloway, Pieter Jelle Visser, Leon J. Thal, Dale Schenk, Zaven Khachaturian, William Thies

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The biological changes that occur in the brains of Alzheimer's disease (AD) patients are thought to begin long before the onset of clinical symptoms. Although current therapeutic agents have been approved only for patients with mild to moderate AD, Alzheimer-type pathology in patients with mild to moderate AD is already quite advanced. One impetus for the development of the concept of mild cognitive impairment (MCI) was the attempt to recognize AD early in its clinical expression and to determine whether it is possible through therapeutic interventions to improve the memory impairment at this stage or delay further progression to dementia. To this end, several clinical trials have been conducted in patients with MCI. On September 8 and 9, 2004 a meeting of the Alzheimer's Association Research Roundtable was held at which experts in the field of MCI convened to review the collective experience from these trials and to consider potential approaches that might improve MCI clinical trials in the future. This article summarizes the presentations and discussions of that meeting.

Original languageEnglish (US)
Pages (from-to)220-233
Number of pages14
JournalAlzheimer's and Dementia
Volume2
Issue number3
DOIs
StatePublished - Jul 2006

Fingerprint

Alzheimer Disease
Research
Clinical Trials
Brain Diseases
Dementia
Pathology
Cognitive Dysfunction
Therapeutics

Keywords

  • Alzheimer's disease
  • Clinical trial design
  • Clinical trials
  • FDA
  • Mild cognitive impairment
  • Outcome measures

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment : What have we learned? / Grundman, Michael; Petersen, Ronald Carl; Bennett, David A.; Feldman, Howard H.; Salloway, Stephen; Visser, Pieter Jelle; Thal, Leon J.; Schenk, Dale; Khachaturian, Zaven; Thies, William.

In: Alzheimer's and Dementia, Vol. 2, No. 3, 07.2006, p. 220-233.

Research output: Contribution to journalArticle

Grundman, M, Petersen, RC, Bennett, DA, Feldman, HH, Salloway, S, Visser, PJ, Thal, LJ, Schenk, D, Khachaturian, Z & Thies, W 2006, 'Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: What have we learned?', Alzheimer's and Dementia, vol. 2, no. 3, pp. 220-233. https://doi.org/10.1016/j.jalz.2006.04.010
Grundman, Michael ; Petersen, Ronald Carl ; Bennett, David A. ; Feldman, Howard H. ; Salloway, Stephen ; Visser, Pieter Jelle ; Thal, Leon J. ; Schenk, Dale ; Khachaturian, Zaven ; Thies, William. / Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment : What have we learned?. In: Alzheimer's and Dementia. 2006 ; Vol. 2, No. 3. pp. 220-233.
@article{1658b9116cb34779a21ce3e653fd5fa6,
title = "Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: What have we learned?",
abstract = "The biological changes that occur in the brains of Alzheimer's disease (AD) patients are thought to begin long before the onset of clinical symptoms. Although current therapeutic agents have been approved only for patients with mild to moderate AD, Alzheimer-type pathology in patients with mild to moderate AD is already quite advanced. One impetus for the development of the concept of mild cognitive impairment (MCI) was the attempt to recognize AD early in its clinical expression and to determine whether it is possible through therapeutic interventions to improve the memory impairment at this stage or delay further progression to dementia. To this end, several clinical trials have been conducted in patients with MCI. On September 8 and 9, 2004 a meeting of the Alzheimer's Association Research Roundtable was held at which experts in the field of MCI convened to review the collective experience from these trials and to consider potential approaches that might improve MCI clinical trials in the future. This article summarizes the presentations and discussions of that meeting.",
keywords = "Alzheimer's disease, Clinical trial design, Clinical trials, FDA, Mild cognitive impairment, Outcome measures",
author = "Michael Grundman and Petersen, {Ronald Carl} and Bennett, {David A.} and Feldman, {Howard H.} and Stephen Salloway and Visser, {Pieter Jelle} and Thal, {Leon J.} and Dale Schenk and Zaven Khachaturian and William Thies",
year = "2006",
month = "7",
doi = "10.1016/j.jalz.2006.04.010",
language = "English (US)",
volume = "2",
pages = "220--233",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment

T2 - What have we learned?

AU - Grundman, Michael

AU - Petersen, Ronald Carl

AU - Bennett, David A.

AU - Feldman, Howard H.

AU - Salloway, Stephen

AU - Visser, Pieter Jelle

AU - Thal, Leon J.

AU - Schenk, Dale

AU - Khachaturian, Zaven

AU - Thies, William

PY - 2006/7

Y1 - 2006/7

N2 - The biological changes that occur in the brains of Alzheimer's disease (AD) patients are thought to begin long before the onset of clinical symptoms. Although current therapeutic agents have been approved only for patients with mild to moderate AD, Alzheimer-type pathology in patients with mild to moderate AD is already quite advanced. One impetus for the development of the concept of mild cognitive impairment (MCI) was the attempt to recognize AD early in its clinical expression and to determine whether it is possible through therapeutic interventions to improve the memory impairment at this stage or delay further progression to dementia. To this end, several clinical trials have been conducted in patients with MCI. On September 8 and 9, 2004 a meeting of the Alzheimer's Association Research Roundtable was held at which experts in the field of MCI convened to review the collective experience from these trials and to consider potential approaches that might improve MCI clinical trials in the future. This article summarizes the presentations and discussions of that meeting.

AB - The biological changes that occur in the brains of Alzheimer's disease (AD) patients are thought to begin long before the onset of clinical symptoms. Although current therapeutic agents have been approved only for patients with mild to moderate AD, Alzheimer-type pathology in patients with mild to moderate AD is already quite advanced. One impetus for the development of the concept of mild cognitive impairment (MCI) was the attempt to recognize AD early in its clinical expression and to determine whether it is possible through therapeutic interventions to improve the memory impairment at this stage or delay further progression to dementia. To this end, several clinical trials have been conducted in patients with MCI. On September 8 and 9, 2004 a meeting of the Alzheimer's Association Research Roundtable was held at which experts in the field of MCI convened to review the collective experience from these trials and to consider potential approaches that might improve MCI clinical trials in the future. This article summarizes the presentations and discussions of that meeting.

KW - Alzheimer's disease

KW - Clinical trial design

KW - Clinical trials

KW - FDA

KW - Mild cognitive impairment

KW - Outcome measures

UR - http://www.scopus.com/inward/record.url?scp=33745015345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745015345&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2006.04.010

DO - 10.1016/j.jalz.2006.04.010

M3 - Article

C2 - 19595891

AN - SCOPUS:33745015345

VL - 2

SP - 220

EP - 233

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 3

ER -